Transgene SA

As of June 30, 2026, Transgene SA carries a market capitalization of 201.74M, placing it among publicly traded companies globally. Its enterprise value stands at 108.89M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Transgene SA's next confirmed earnings release is scheduled for March 31, 2027.

As of June 30, 2026, Transgene SA has 278.26M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Transgene SA maintains a current ratio of 9.40, meaning it holds 9.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 23, 2026, Transgene SA's stock has declined approximately 49.44% over the past 52 weeks. The 50-day moving average sits at 0.78, while the 200-day moving average is 0.79.

These figures are as of June 30, 2026. Total book value stands at 109.20M, with working capital of 89.88M providing operational flexibility.

Transgene SA's most recent stock split took place on June 18, 2019 with a 39:40 split ratio.